Organon Financial Statements
NYSE: OGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Organon revenue and earnings
In fiscal 2025, Organon generated $6.22 billion in revenue, down 2.9% from fiscal 2024, its first annual decline since 2022. Net income was $187.0 million (-78.4% year over year), for a net margin of 3.0% versus a median of 16.3% in the prior 5 years. Gross margin was 53.3% (down from 58.0%).
Diluted earnings per share came in at $0.72, down from $3.33. Over the last 5 fiscal years, OGN's revenue has grown at a -1.0% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Organon income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.22B | 6.40B | 6.26B | 6.17B | 6.30B | 6.53B | 7.78B |
| Revenue growth (YoY) | -2.92% | +2.24% | +1.44% | -2.06% | -3.49% | -16.01% | — |
| Cost of Revenue | 2.90B | 2.69B | 2.52B | 2.29B | 2.38B | 2.12B | 2.27B |
| Gross Profit | 3.31B | 3.71B | 3.75B | 3.88B | 3.92B | 4.41B | 5.50B |
| Research & Development | 366.00M | 469.00M | 528.00M | 471.00M | 443.00M | 210.00M | 220.00M |
| Selling, General & Admin | 1.72B | 1.76B | 1.89B | 1.70B | 1.67B | 1.36B | 1.44B |
| Interest Expense | 504.00M | 520.00M | 527.00M | 422.00M | 258.00M | 0 | 0 |
| Pretax Income | 425.00M | 807.00M | 673.00M | 1.12B | 1.53B | 2.75B | 3.70B |
| Income Tax | 238.00M | -57.00M | -350.00M | 205.00M | 178.00M | 496.00M | 390.00M |
| Net Income | 187.00M | 864.00M | 1.02B | 917.00M | 1.35B | 2.16B | 3.22B |
| Net Income growth (YoY) | -78.36% | -15.54% | +11.56% | -32.12% | -37.45% | -32.88% | — |
| EPS (Basic) | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.69 |
| EPS (Diluted) | 0.72 | 3.33 | 3.99 | 3.59 | 5.31 | 8.52 | 12.69 |
| Shares Outstanding (Basic) | 259.50M | 257.05M | 255.24M | 254.08M | 253.54M | 253.52M | 253.52M |
| Shares Outstanding (Diluted) | 260.76M | 259.15M | 256.27M | 255.17M | 254.19M | 253.52M | 253.52M |
| Gross Margin | 53.30% | 58.02% | 59.84% | 62.84% | 62.21% | 67.56% | 70.76% |
| Net Margin | 3.01% | 13.49% | 16.33% | 14.85% | 21.43% | 33.07% | 41.38% |
This table shows 7 annual periods of Organon's income statement, from FY 2025 back to FY 2019, across 15 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow OGN's reporting calendar. What is a income statement?